Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Parkinson’s Disease Therapeutics Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Parkinson’s Disease Therapeutics Industry
  • 1.7 COVID-19 Impact: Parkinson’s Disease Therapeutics Market Trends

    • 2 Global Parkinson’s Disease Therapeutics Quarterly Market Size Analysis

    • 2.1 Parkinson’s Disease Therapeutics Business Impact Assessment - COVID-19
      • 2.1.1 Global Parkinson’s Disease Therapeutics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Parkinson’s Disease Therapeutics Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Parkinson’s Disease Therapeutics Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Parkinson’s Disease Therapeutics Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Parkinson’s Disease Therapeutics Market
    • 3.4 Key Players Parkinson’s Disease Therapeutics Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Parkinson’s Disease Therapeutics Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Oral
      • 1.4.2 Transdermal
      • 1.4.3 Subcutaneous
      • 1.4.4 Intestinal Infusion
    • 4.2 By Type, Global Parkinson’s Disease Therapeutics Market Size, 2019-2021

    5 Impact of Covid-19 on Parkinson’s Disease Therapeutics Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Clinics
      • 5.5.3 Others
    • 5.2 By Application, Global Parkinson’s Disease Therapeutics Market Size, 2019-2021
      • 5.2.1 By Application, Global Parkinson’s Disease Therapeutics Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Abbvie
      • 7.1.1 Abbvie Business Overview
      • 7.1.2 Abbvie Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.1.3 Abbvie Parkinson’s Disease Therapeutics Product Introduction
      • 7.1.4 Abbvie Response to COVID-19 and Related Developments
    • 7.2 Biogen
      • 7.2.1 Biogen Business Overview
      • 7.2.2 Biogen Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.2.3 Biogen Parkinson’s Disease Therapeutics Product Introduction
      • 7.2.4 Biogen Response to COVID-19 and Related Developments
    • 7.3 Boehringer Ingelheim GmbH
      • 7.3.1 Boehringer Ingelheim GmbH Business Overview
      • 7.3.2 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.3.3 Boehringer Ingelheim GmbH Parkinson’s Disease Therapeutics Product Introduction
      • 7.3.4 Boehringer Ingelheim GmbH Response to COVID-19 and Related Developments
    • 7.4 F. Hoffman-La Roche
      • 7.4.1 F. Hoffman-La Roche Business Overview
      • 7.4.2 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.4.3 F. Hoffman-La Roche Parkinson’s Disease Therapeutics Product Introduction
      • 7.4.4 F. Hoffman-La Roche Response to COVID-19 and Related Developments
    • 7.5 GlaxoSmithKline
      • 7.5.1 GlaxoSmithKline Business Overview
      • 7.5.2 GlaxoSmithKline Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.5.3 GlaxoSmithKline Parkinson’s Disease Therapeutics Product Introduction
      • 7.5.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.6 H. Lundbeck A/S
      • 7.6.1 H. Lundbeck A/S Business Overview
      • 7.6.2 H. Lundbeck A/S Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.6.3 H. Lundbeck A/S Parkinson’s Disease Therapeutics Product Introduction
      • 7.6.4 H. Lundbeck A/S Response to COVID-19 and Related Developments
    • 7.7 Impax Labs
      • 7.7.1 Impax Labs Business Overview
      • 7.7.2 Impax Labs Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.7.3 Impax Labs Parkinson’s Disease Therapeutics Product Introduction
      • 7.7.4 Impax Labs Response to COVID-19 and Related Developments
    • 7.8 Newron Pharmaceuticals SpA
      • 7.8.1 Newron Pharmaceuticals SpA Business Overview
      • 7.8.2 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.8.3 Newron Pharmaceuticals SpA Parkinson’s Disease Therapeutics Product Introduction
      • 7.8.4 Newron Pharmaceuticals SpA Response to COVID-19 and Related Developments
    • 7.9 Novartis AG
      • 7.9.1 Novartis AG Business Overview
      • 7.9.2 Novartis AG Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.9.3 Novartis AG Parkinson’s Disease Therapeutics Product Introduction
      • 7.9.4 Novartis AG Response to COVID-19 and Related Developments
    • 7.10 Orion Corporation
      • 7.10.1 Orion Corporation Business Overview
      • 7.10.2 Orion Corporation Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.10.3 Orion Corporation Parkinson’s Disease Therapeutics Product Introduction
      • 7.10.4 Orion Corporation Response to COVID-19 and Related Developments
    • 7.11 Teva Pharmaceutical Industries Ltd.
      • 7.11.1 Teva Pharmaceutical Industries Ltd. Business Overview
      • 7.11.2 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.11.3 Teva Pharmaceutical Industries Ltd. Parkinson’s Disease Therapeutics Product Introduction
      • 7.11.4 Teva Pharmaceutical Industries Ltd. Response to COVID-19 and Related Developments
    • 7.12 UCB S.A.
      • 7.12.1 UCB S.A. Business Overview
      • 7.12.2 UCB S.A. Parkinson’s Disease Therapeutics Quarterly Revenue, 2020
      • 7.12.3 UCB S.A. Parkinson’s Disease Therapeutics Product Introduction
      • 7.12.4 UCB S.A. Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Parkinson’s Disease Therapeutics, including the following market information:
      Global Parkinson’s Disease Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Parkinson’s Disease Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Parkinson’s Disease Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Parkinson’s Disease Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Abbvie, Biogen, Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline, H. Lundbeck A/S, Impax Labs, Newron Pharmaceuticals SpA, Novartis AG, Orion Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Oral
      Transdermal
      Subcutaneous
      Intestinal Infusion

      Based on the Application:
      Hospitals
      Clinics
      Others

      Buy now